索拉非尼与白介素联合治疗晚期肾癌的效果分析

Efficacy of Sorafenib and Interleukin in the Treatment of Advanced Renal Cell Carcinoma

目的探讨索拉非尼联合白介素治疗晚期肾癌患者的临床效果。方法以晚期肾癌患者共53例作为研究对象,随机分为观察组(26例)以及对照组(27例),对照组患者给予白介素-2治疗,观察组患者给予索拉非尼联合白介素-2治疗,对比两组患者治疗效果差异。结果观察组缓解率61.5%,对照组缓解率40.7%,对比差异具有统计学意义(P<0.05)。结论索拉非尼联合白介素治疗晚期肾癌患者效果良好。

Objective To investigate the clinical effect of sorafenib combined with interleukin-2 therapy in patients with advanced renal cell carcinoma. Methods A total of 53 patients with advanced renal cell carcinoma（RCC）as the object of study,were randomly divided into observation group（26 cases）and control group（27 cases）. In control group were treated with interleukin-2 in the treatment,the observation group was treated with sorafenib combined with interleukin-2 treatment,compared two groups of patients with treatment effect differences. Results The remission rate of the observation group was 61.5%,the control group was 40.7%,the difference was significant（P〈0.05）. Conclusion Sorafenib combined with interleukin treatment of advanced renal cell carcinoma patients is good.